newsfilter
← Latest News
GlobeNewswire·

Clearmind Medicine Announces Filing of European Patent Application for Novel Psychedelic Compounds for the Treatment of PTSD

  • Clearmind Medicine Inc. filed a European patent application for innovative non-hallucinogenic psychedelic compounds targeting PTSD and other mental health disorders.
  • The filing is part of an exclusive worldwide licensing agreement with Yissum Research Development Company, granting Clearmind global rights to develop, manufacture, and commercialize the compounds.
  • The global PTSD treatment market was valued at approximately USD 18.5 billion in 2025 and is projected to reach USD 30.2 billion by 2035 with a CAGR of 5.0%.
  • The patent filing strengthens Clearmind's intellectual property position in Europe amidst President Donald J. Trump's April 18, 2026 Executive Order accelerating psychedelic therapy research & regulatory review for serious mental health conditions.
  • Clearmind's current intellectual portfolio includes 19 patent families with 31 granted patents, & the company intends to seek additional patents & pursue opportunistic IP acquisitions.
  • Shares of Clearmind trade on the Nasdaq under the symbol "CMND."